Efficacy and Safety of Lumasiran for Infants and Young Children With Primary Hyperoxaluria Type 1: 12-Month Analysis of the Phase 3 ILLUMINATE-B Trial

Friday, April 22, 2022

6:15 PM – 6:30 PM US MT

Location: Convention Center: 708/710/712

CE: Enduring CME: 0.25

Publication Number: 595.1

Mini Michael, Texas Children’s Hospital/Baylor College of Medicine, Houston, TX, United States; Wesley N. Hayes, Great Ormond Street Hospital, London, England, United Kingdom; David J. Sas, Mayo Clinic Children's Center, Rochester, MN, United States; Daniella Magen, Rambam Health Care Campus, Haifa, HaZafon, Israel; Hadas Shasha-Lavsky, Galilee Medical Center, Tivon, HaZafon, Israel; Anne-Laure Sellier-Leclerc, hôpital femme mère enfant - hospices civils de Lyon, Bron, Rhone-Alpes, France; Julien HOGAN, Robert Debré Hospital, APHP, Paris, Ile-de-France, France; Taylor Ngo, Alnylam Pharmaceuticals, Cambridge, MA, United States; Marianne T. Sweetser, Alnylam Pharmaceuticals, Inc, Cambridge, MA, United States; John M. Gansner, Alnylam Pharmaceuticals, Cambridge, MA, United States; Yaacov Frishberg, Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel

Presenting Author(s)

Mini Michael, MD
Associate Professor, Pediatric Nephrology Division
Texas Children’s Hospital/Baylor College of Medicine
Houston, Texas, United States

Full Presentation

Participants should be aware of the following financial/non-financial relationships:

Mini Michael, MD: ● Alnylam Pharmaceuticals (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator).

Wesley N. Hayes, MBBChir MEng MA: I do not have any relevant financial / non-financial relationships with any proprietary interests.

David J. Sas, DO, MPH: ● Alnylam (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant).

Daniella Magen, M.D.: ● Alnylam (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator).

Hadas Shasha-Lavsky, MD: ● Alnylam (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator).

Anne-Laure Sellier-Leclerc, n/a: ● ALNYLAM (Products/Services: Speaker Honorarium including speakers bureau, symposia, and expert witness, Board Member or Executive Role).

Julien HOGAN, HOGAN, MD, PhD: ● Alnylam (Currently Ongoing) (Products/Services: Consultant, Advisory Committee).
● Takeda (Ended In the Past 24 Months) (Products/Services: Speaker Honorarium including speakers bureau, symposia, and expert witness).
● Traverse (Currently Ongoing) (Products/Services: Advisory Committee).

Taylor Ngo, MPH: ● Alnylam Pharmaceuticals (Currently Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds).

Marianne T. Sweetser, MD, PhD: ● Alnylam Pharmaceuticals (Currently Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds).

John M. Gansner, MD, PhD: ● Alnylam Pharmaceuticals (Currently Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds).

Yaacov Frishberg, MD: ● Alnylam Pharmaceuticals (Currently Ongoing) (Products/Services: Research Support including clinical trials & the principal or named investigator, Consultant).